ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1096882
CHEMBL1096882
Compound Name FLUDARABINE PHOSPHATE
ChEMBL Synonyms FLUDARABINE | OFORTA | FLUDARABINE PHOSPHATE | FLUDARA
Max Phase 4 (Approved)
Trade Names FLUDARA | FLUDARABINE PHOSPHATE | OFORTA
Molecular Formula C10H13FN5O7P

Additional synonyms for CHEMBL1096882 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES Nc1nc(F)nc2c1ncn2[C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]3O
Standard InChI InChI=1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6 ...
Download InChI
Standard InChI Key GIUYCYHIANZCFB-FJFJXFQQSA-N

Sources

  • British National Formulary
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1096882

Molecule Features

CHEMBL1096882 compound icon
Drug Type:Natural Product-derived Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
DNA polymerase (alpha/delta/epsilon) inhibitor DNA polymerase (alpha/delta/epsilon) FDA
Ribonucleoside-diphosphate reductase RR1 inhibitor Ribonucleoside-diphosphate reductase RR1 FDA PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Immune System DiseasesD007154EFO:0000540immune system disease2ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-CellD015451EFO:0000095chronic lymphocytic leukemia4ClinicalTrials
FDA
Leukemia, LymphoidD007945EFO:0004289lymphoid leukemia2ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveD015464EFO:0000339chronic myelogenous leukemia2ClinicalTrials
Leukemia, Myelomonocytic, JuvenileD054429EFO:1000309Juvenile Myelomonocytic Leukemia2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma2ClinicalTrials
Multiple SclerosisD009103EFO:0003885multiple sclerosis2ClinicalTrials
SarcomaD012509EFO:0000691sarcoma2ClinicalTrials
Anemia, AplasticD000741EFO:0006927severe aplastic anemia3ClinicalTrials
Breast NeoplasmsD001943EFO:0003869breast neoplasm2ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000708squamous cell lung carcinoma1ClinicalTrials
Crohn DiseaseD003424EFO:0000384Crohn's disease2ClinicalTrials
Fanconi AnemiaD005199Orphanet:84Fanconi anemia2ClinicalTrials
Graft vs Host DiseaseD006086EFO:0004599acute graft vs. host disease2ClinicalTrials
Leukemia, Prolymphocytic, B-CellD054403EFO:1000102B-Cell Prolymphocytic Leukemia2ClinicalTrials
Metabolic DiseasesD008659EFO:0000589metabolic disease1ClinicalTrials
Myeloproliferative DisordersD009196EFO:0004251myeloproliferative disorder2ClinicalTrials
Severe Combined ImmunodeficiencyD016511Orphanet:183660Severe combined immunodeficiency1ClinicalTrials
Anemia, Sickle CellD000755Orphanet:232Sickle cell anemia3ClinicalTrials
Esophageal NeoplasmsD004938EFO:0002916esophageal carcinoma2ClinicalTrials
GliomaD005910EFO:0000326central nervous system cancer1ClinicalTrials
Hematologic DiseasesD006402EFO:0005803hematological system disease2ClinicalTrials
MesotheliomaD008654EFO:0000588mesothelioma1ClinicalTrials
NeuroblastomaD009447EFO:0000621neuroblastoma2ClinicalTrials
OsteopetrosisD010022Orphanet:2781Osteopetrosis2ClinicalTrials
Ovarian NeoplasmsD010051EFO:0001075ovarian carcinoma2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma1ClinicalTrials
PsoriasisD011565EFO:0000676psoriasis2ClinicalTrials
Anemia, AplasticD000741HP:0001915aplastic anemia3ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0000681renal cell carcinoma2ClinicalTrials
GlioblastomaD005909EFO:0000519glioblastoma multiforme1ClinicalTrials
Granulomatous Disease, ChronicD006105Orphanet:379Chronic granulomatous disease2ClinicalTrials
Leukemia, Erythroblastic, AcuteD004915EFO:1001257acute erythroblastic leukemia2ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia3ClinicalTrials
NeoplasmsD009369EFO:0000311cancer4ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
ClinicalTrials
Thyroid NeoplasmsD013964EFO:0002892thyroid carcinoma1ClinicalTrials
Waldenstrom MacroglobulinemiaD008258EFO:0002616macroglobulinemia2ClinicalTrials
HistiocytosisD015614HP:0100727Histiocytosis2ClinicalTrials
Hodgkin DiseaseD006689EFO:0000183Hodgkins lymphoma2ClinicalTrials
Leukemia, Biphenotypic, AcuteD015456EFO:0000094B-cell acute lymphoblastic leukemia1ClinicalTrials
Lymphoma, Non-HodgkinD008228EFO:0005952non-Hodgkins lymphoma3ClinicalTrials
MelanomaD008545EFO:0000389cutaneous melanoma3ClinicalTrials
Sarcoma, EwingD012512EFO:0000174Ewing sarcoma1ClinicalTrials
Sezary SyndromeD012751EFO:1000785Sezary's disease1ClinicalTrials
ThalassemiaD013789EFO:1001996Thalassemia2ClinicalTrials
AnemiaD000740EFO:0004272anemia1ClinicalTrials
Hematologic NeoplasmsD019337EFO:0001642lymphoid neoplasm2ClinicalTrials
Kidney NeoplasmsD007680EFO:0003865kidney neoplasm1ClinicalTrials
Leukemia, Prolymphocytic, T-CellD015461EFO:1000560T-Cell Prolymphocytic Leukemia2ClinicalTrials
Head and Neck NeoplasmsD006258EFO:0006859head and neck malignant neoplasia1ClinicalTrials
Leukemia, Plasma CellD007952EFO:0006475plasma cell leukemia2ClinicalTrials
LymphomaD008223EFO:0000574lymphoma3ClinicalTrials
Lymphoma, Large B-Cell, DiffuseD016403EFO:0000403diffuse large B-cell lymphoma2ClinicalTrials
MelanomaD008545EFO:0000756melanoma3ClinicalTrials
MelanomaD008545EFO:0002617metastatic melanoma3ClinicalTrials
Mycosis FungoidesD009182EFO:1001051mycosis fungoides1ClinicalTrials
Myelodysplastic SyndromesD009190EFO:0000198myelodysplastic syndrome3ClinicalTrials
Nasopharyngeal NeoplasmsD009303EFO:0004252nasopharyngeal neoplasm1ClinicalTrials
Wiskott-Aldrich SyndromeD014923Orphanet:906Wiskott-Aldrich syndrome1ClinicalTrials
Anemia, RefractoryD000753EFO:0003802refractory anemia2ClinicalTrials
Arthritis, PsoriaticD015535EFO:0003778psoriatic arthritis2ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0002890renal carcinoma2ClinicalTrials
DiseaseD004194EFO:0000408disease1ClinicalTrials
Epidermolysis BullosaD004820EFO:1000690epidermolysis bullosa2ClinicalTrials
LeukemiaD007938EFO:0000565leukemia3ClinicalTrials
Lupus Erythematosus, SystemicD008180EFO:0002690systemic lupus erythematosus2ClinicalTrials
Lymphoma, FollicularD008224EFO:0000096neoplasm of mature B-cells3ClinicalTrials
Lymphoma, Mantle-CellD020522EFO:1001469Mantle cell lymphoma3ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia3ClinicalTrials
Primary MyelofibrosisD055728EFO:0002430primary myelofibrosis2ClinicalTrials
Scleroderma, SystemicD012595EFO:0000717systemic scleroderma2ClinicalTrials
beta-ThalassemiaD017086Orphanet:848Beta-thalassemia2ClinicalTrials

Clinical Data

ClinicalTrials.gov FLUDARABINE PHOSPHATE
The Cochrane Collaboration FLUDARABINE PHOSPHATE

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1096882. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL226 Adenosine A1 receptor Homo sapiens 1.000
CHEMBL256 Adenosine A3 receptor Homo sapiens 1.000
CHEMBL4398 Purinergic receptor P2Y2 Homo sapiens 1.000
CHEMBL318 Adenosine A1 receptor Rattus norvegicus 1.000
CHEMBL5720 P2Y purinoceptor 1 Meleagris gallopavo 1.000
CHEMBL5662 2,3-dihydroxybenzoate-AMP ligase Mycobacterium tuberculosis 1.000
CHEMBL302 Adenosine A2a receptor Rattus norvegicus 1.000
CHEMBL3360 Adenosine A3 receptor Rattus norvegicus 1.000
CHEMBL4714 Pyrimidinergic receptor P2Y6 Homo sapiens 1.000
CHEMBL1795117 Histone-lysine N-methyltransferase, H3 lysine-79 specific Homo sapiens 1.000
CHEMBL2664 Adenosylhomocysteinase Homo sapiens 1.000
CHEMBL2123 Pyrimidinergic receptor P2Y4 Homo sapiens 1.000
CHEMBL4315 Purinergic receptor P2Y1 Homo sapiens 1.000
CHEMBL6069 Pantothenate synthetase Mycobacterium tuberculosis 1.000
CHEMBL1293237 Bloom syndrome protein Homo sapiens 1.000
CHEMBL2304404 Adenosine A1 receptor Cavia porcellus 1.000
CHEMBL251 Adenosine A2a receptor Homo sapiens 1.000
CHEMBL1997 Equilibrative nucleoside transporter 1 Homo sapiens 1.000
CHEMBL3712907 Transmembrane domain-containing protein TMIGD3 Homo sapiens 1.000
CHEMBL2966 Adenosine deaminase Bos taurus 1.000



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL226 Adenosine A1 receptor Homo sapiens 1.000
CHEMBL256 Adenosine A3 receptor Homo sapiens 1.000
CHEMBL1795117 Histone-lysine N-methyltransferase, H3 lysine-79 specific Homo sapiens 1.000
CHEMBL3360 Adenosine A3 receptor Rattus norvegicus 1.000
CHEMBL5662 2,3-dihydroxybenzoate-AMP ligase Mycobacterium tuberculosis 1.000
CHEMBL5720 P2Y purinoceptor 1 Meleagris gallopavo 1.000
CHEMBL2664 Adenosylhomocysteinase Homo sapiens 1.000
CHEMBL318 Adenosine A1 receptor Rattus norvegicus 1.000
CHEMBL4398 Purinergic receptor P2Y2 Homo sapiens 1.000
CHEMBL302 Adenosine A2a receptor Rattus norvegicus 1.000
CHEMBL2123 Pyrimidinergic receptor P2Y4 Homo sapiens 1.000
CHEMBL4714 Pyrimidinergic receptor P2Y6 Homo sapiens 1.000
CHEMBL251 Adenosine A2a receptor Homo sapiens 1.000
CHEMBL4315 Purinergic receptor P2Y1 Homo sapiens 1.000
CHEMBL2966 Adenosine deaminase Bos taurus 1.000
CHEMBL2982 Adenosine kinase Toxoplasma gondii 1.000
CHEMBL4518 Purinergic receptor P2Y14 Homo sapiens 1.000
CHEMBL5328 Thymidylate synthase Lactobacillus casei 1.000
CHEMBL2304404 Adenosine A1 receptor Cavia porcellus 1.000
CHEMBL1997 Equilibrative nucleoside transporter 1 Homo sapiens 1.000

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
365.2 365.0537 -1.72 4 186.07 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
10 5 0 12 6 2


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
1.86 1.3 -3.37 -7.62 2 24 0.31

Structural Alerts

There are 7 structural alerts for CHEMBL1096882. To view alerts please click here.

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01B - ANTIMETABOLITES
L01BB - Purine analogues
L01BB05 - fludarabine

ChemSpider ChemSpider:GIUYCYHIANZCFB-FJFJXFQQSA-N
DailyMed fludarabine phosphate

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1096882



ACToR 75607-67-9
Brenda 58138 21263 137581 129164 137582 66913 145776 112868 128896 112402 137769
ChEBI 63599
DrugCentral 1189
eMolecules 3715941
EPA CompTox Dashboard DTXSID2023060
FDA SRS 1X9VK9O1SC
Human Metabolome Database HMDB0015206
IBM Patent System F2442429D1E764079682C93C755A4C5C
LINCS LSM-45862
MolPort MolPort-003-666-877
Nikkaji J535.382C
PharmGKB PA449655
PubChem 30751
PubChem: Drugs of the Future 12012906
PubChem: Thomson Pharma 14877054 14754977
Selleck Fludara
SureChEMBL SCHEMBL3511
ZINC ZINC000003927870

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/GIUYCYHIANZCFB-FJFJXFQQSA-N spacer
spacer